Why yes, it will apparently!
Ask your doctor before using carBAMazepine together with ARIPiprazole. Using these medications together may cause ARIPiprazole to be less effective. If you take both medications together, tell your doctor if you have an increase in psychotic symptoms. You may need a dose adjustment if you take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Wave
April 3, 2016, 1:20pm
3
I told you already @anon80629714 - YES
Tegretol reduces the other medications levels - its not just Abilify.
Other medications are affected as well, includng birth control pills, etc…
Your doctor should have made the adjustments and raised your Abilify already
2 Likes
Wave
April 3, 2016, 3:58pm
4
Tegretol eats about 70 percent of Abilify!
I know because I was taking both of these meds at the same time, for a long time.
1 Like
And I only take 5mg. I will talk to my doc.
1 Like
Sharp
April 3, 2016, 5:46pm
6
Really! THt is great. I’m going to look into this.
1 Like
No, wave is saying that it reduces the effectiveness of abilify by 70%.
1 Like
Sharp
April 3, 2016, 6:37pm
8
Oh! I thought it meant side effects. Oh dear. That was a close call then XD
1 Like
Yes! You’d need to up your dosage. L-theanine has been a miracle supplement for me in reducing abilify side effects. That and a low powered bcomplex.
1 Like
E Spina, F Pisani and J de Leon,
Pharmacological research , Apr 2016
Antiepileptic drugs (AEDs) are frequently co-prescribed with new antidepressants (ADs) or new antipsychotics (APs). A PubMed search with no time limit was used to update the review of the clinically significant pharmacokinetic (PK) drug interactions DIs (DIs) between AEDs with new ADs and APs. Our best interpretation of what to expect regarding dosing changes in the average patient after combining AEDs with new ADs or new APs is summarized on updated tables that integrate the information on in vitro metabolism studies, therapeutic drug monitoring (TDM) studies, case report/series and prospective studies. There will be a need to periodically update these dose correction factors as new knowledge becomes available. These tables will provide some orientation to clinicians with no TDM access and may also encourage clinicians to further study TDM. The clinical relevance of the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone on new ADs and new APs and the inhibitory properties of valproic acid and some new ADs, are relatively well understood. On the other hand, PK DI studies combining new AEDs with weak inductive properties (particularly oxcarbazepine doses≥1200mg/day), topiramate doses≥400mg/day, clobazam, eslicarbazepine, and rufinamide), with new ADs and new APs are needed. Valproic acid may be 1) an inhibitor and/or inducer of clozapine and olanzapine with potential for clinically relevant DIs, 2) an inhibitor of paliperidone, and 3) a weak inducer of aripiprazole. Fluoxetine and fluvoxamine are relevant inhibitors of phenytoin and valproic acid and possibly of clobazam, lacosamide, phenobarbital, or primidone.
https://sci-hub.io/10.1016/j.phrs.2016.02.014 (PDF)
CS Shastry, AA Shafeeque and BJ Ashwathnarayana,
Indian journal of pharmacology , Mar-Apr 2013
Aripiprazole, a new atypical antipsychotic drug extensively metabolized by enzyme CYP3A4, is found to produce asymptomatic elevation of serum transaminase levels on long-term treatment. The present study aims to evaluate the hepatotoxic effect of aripiprazole when coprescribed with carbamazepine and fluvoxamine.The rats were subjected to chronic treatment with two different doses, therapeutic dose (TD) and maximum therapeutic dose (MTD), of aripiprazole in combination with carbamazepine and fluvoxamine. The changes in hepatic function was assessed by various biochemical liver enzyme markers like serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase (ALP), total bilirubin, histological studies, and physical parameters (liver weight, liver volume, and body weight).The combination of aripiprazole with fluvoxamine at both TD and MTD showed the hepatic damage and significant elevation in serum transaminase level which is supported by histological reports. The coadministration of aripiprazole with carbamazepine leads to significant decrease in blood concentration of aripiprazole possibly due to induction of enzyme CYP3A4 resulting in loss or reduction of clinical efficacy.There would be an accumulation of aripiprazole when coadministered with fluvoxamine, a known inhibitor of CYP3A4, leading to hepatic damage and reduction in aripiprazole when administered along with carbamazepine. Therefore, aripiprazole with fluvoxamine and carbamazepine should be coprescribed with caution. The patients should be monitored for signs of adverse effects like hepatic damage or decreased efficacy of these drugs.
1 Like
Thanks although this is very confusing. I’ll try to make sense of it lol